Posted by Michael Wonder on 20 Apr 2021
Amgen launches Biomarker Assist, a program to help more patients with non-small cell lung cancer gain access to biomarker testing
19 April 2021 - Half of all patients with non-small cell lung cancer have oncogene mutations, yet many patients are not tested to screen for biomarker.
Amgen today announced the launch of Biomarker Assist, a program to help more patients with metastatic (stage IV) non-small cell lung cancer gain access to biomarker testing.
Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.
